R Swamy Venuturupalli, MD
Rheumatology · Beverly Hills, CANPI 1063437648
Payments from drug & device makers
Across 533 payments — averaging $1724.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Navidea Biopharmaceuticals, Inc.$208K
- Pfizer$147K
- Argenx US, Inc.$138K
- Novartis$109K
- Mallinckrodt Hospital Products Inc.$85K
- E.r. Squibb & Sons, L.L.C.$83K
- plus $149K from 27 others
Across 9 payments — averaging $2268.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
- Argenx US, Inc.$420
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Navidea Biopharmaceuticals, Inc. | 7 | $208,271 |
| Pfizer | 72 | $147,038 |
| Argenx US, Inc. | 64 | $137,581 |
| Novartis | 77 | $108,590 |
| Mallinckrodt Hospital Products Inc. | 6 | $85,207 |
| E.r. Squibb & Sons, L.L.C. | 9 | $83,353 |
| Janssen Research & Development, LLC | 6 | $56,262 |
| Mallinckrodt Enterprises LLC | 3 | $46,500 |
| EMD Serono, Inc. | 1 | $29,352 |
| Kiniksa Pharmaceuticals, Ltd. | 38 | $10,818 |
| AbbVie | 101 | $2,307 |
| Amgen(2 entities) | 85 | $2,196 |
| Johnson & Johnson(2 entities) | 17 | $455 |
| Radius Health, Inc. | 9 | $226 |
| UCB, Inc. | 5 | $164 |
| GSK | 7 | $130 |
| ANI Pharmaceuticals, Inc. | 3 | $99 |
| Gilead | 1 | $88 |
| Genentech USA, Inc. | 4 | $84 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $51 |
| AstraZeneca(2 entities) | 2 | $42 |
| Avanos Medical | 2 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Sobi, Inc | 1 | $33 |
| Fidia Pharma USA Inc. | 1 | $33 |
| Zimmer Biomet | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Medexus Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Celltrion USA Inc. | 1 | $15 |
How this compares
$919,137 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Beverly Hills
- Daniel WallaceBeverly Hills$2.2M
- Stuart SilvermanBeverly Hills$924K
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.